Identification of diagnostic serum protein profiles of glioblastoma patients by Elstner, Anja et al.
CLINICAL STUDY – PATIENT STUDY
Identiﬁcation of diagnostic serum protein proﬁles
of glioblastoma patients
Anja Elstner • Florian Stockhammer • Trong-Nghia Nguyen-Dobinsky •
Quang Long Nguyen • Ingo Pilgermann • Amanjit Gill • Anke Guhr •
Tingguo Zhang • Kajetan von Eckardstein • Thomas Picht • Julian Veelken •
Robert L. Martuza • Andreas von Deimling • Andreas Kurtz
Received: 4 August 2008/Accepted: 21 June 2010/Published online: 9 July 2010
 Springer Science+Business Media, LLC. 2010
Abstract Diagnosis of a glioblastoma (GBM) is triggered
by the onset of symptoms and is based on cerebral imaging
and histological examination. Serum-based biomarkers may
support detection of GBM. Here, we explored serum protein
concentrations of GBM patients and used data mining to
explore proﬁles of biomarkers and determine whether these
are associated with the clinical status of the patients. Gene
and protein expression data for astrocytoma and GBM were
used to identify secreted proteins differently expressed in
tumors and in normal brain tissues. Tumor expression and
serum concentrations of 14 candidate proteins were ana-
lyzed for 23 GBM patients and nine healthy subjects. Data-
mining methods involving all 14 proteins were used as an
initial evaluation step to ﬁnd clinically informative proﬁles.
Data mining identiﬁed a serum protein proﬁle formed by
BMP2, HSP70, and CXCL10 that enabled correct assign-
ment to the GBM group with speciﬁcity and sensitivity of
89 and 96%, respectively (p\0.0001, Fischer’s exact test).
Survival for more than 15 months after tumor resection was
associated with a proﬁle formed by TSP1, HSP70, and
IGFBP3, enabling correct assignment in all cases
(p\0.0001, Fischer’s exact test). No correlation was found
with tumor size or age of the patient. This study shows that
robust serum proﬁles for GBM may be identiﬁed by data
mining on the basis of a relatively small study cohort.
Proﬁles of more than one biomarker enable more speciﬁc
assignment to the GBM and survival group than those based
on single proteins, conﬁrming earlier attempts to correlate
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Introduction
The glioblastoma (GBM) is a high-grade astrocytoma and
is one of the most aggressive brain tumors. In most cases it
is diagnosed only after clinical symptoms become apparent
and depends on histological investigation of tumor samples
obtained by biopsy or resection. Gene and protein expres-
sion proﬁling of astrocytic tumors, including cDNA
microarray gene expression proﬁling of brain tumor tissue
and cell lines [1–11] and quantitative proteomics analysis
[12, 13], have recently been proposed as additional and
reﬁned diagnostic criteria. The analysis of microvesicles of
glioma cells in culture revealed RNA and proteins that are
potentially useful biomarkers [14]. Secreted proteins coded
by astrocytoma-expressed genes may be detectable in the
circulation and are thus candidates for noninvasive veriﬁ-
cation of diagnosis. Serum biomarkers have been detected
by analysis of gene expression proﬁles of non-brain
tumors, with promising results [15–17]. A few secreted
proteins, including soluble CD95, YKL-40, frizzled, serum
protein kinases, apolipoprotein E, cell adhesion molecules,
and angiopoietins-1 and 2, have been proposed as potential
serum biomarkers of astrocytomas [18–27]. None of these
proteins alone was sufﬁciently speciﬁc and sensitive to
serve as a diagnostic marker.
Because previous attempts to ﬁnd surrogate serum
markers for GBM failed when based on a single or only few
candidate factors, we attempted to analyze multiple factors
to identify proﬁles associated with GBM. We screened
astrocytoma gene and protein expression data bases for
extracellular and secreted proteins differently expressed in
astrocytoma. The serum concentrations of the identiﬁed
proteins were determined for GBM patients by use of
standard ELISA techniques. To identify a protein concen-
tration pattern as a predictive model for the presence of a
GBM, we chose to use unsupervised data mining as a ﬁrst
identiﬁcation tool because it enables recognition of struc-
tures in the available data independent of a preset hypoth-
esis [28]. Because of the limited sample size, we also used
standard statistics for data analysis. The data show that
serum proﬁles can be deﬁned which are associated with
GBM diagnosis and survival within the analyzed sample.
Methods
The concentrations of 14 secreted candidate proteins were
identiﬁed from data banks on astrocytoma gene expression.
Tumor-speciﬁc protein expression was veriﬁed on tissue
microarrays by immunohistochemistry. The concentrations
of the protein were analyzed in the serum of 23 patients
with GBM, and 12 control subjects. The data were proﬁled
and associated with the disease by data mining and con-
ﬁrmed by bootstrapping. Filters were developed for serum
protein proﬁles that enable diagnosis of GBM and predic-
tion of survival of more or less than 15 months post GBM
diagnosis within the study cohort.
Patient recruitment
Twenty-three patients with GBM were recruited at the
Departments of Neurosurgery at Massachusetts General
Hospital,Boston,USA,Charite ´-Universita ¨tsmedizinBerlin,
Germany, Helios Klinikum Berlin-Buch, Germany, and
Vivantes Klinikum Berlin-Neuko ¨lln, Germany. All tumor
patients underwent gross tumor resection. Sera from nine
healthy controls were acquired from the Department of
Neurosurgery at Helios Klinikum Berlin. Control sera from
three patients with rheumatoid arthritis treated with gluco-
corticoids (5–15 mg prednisolone/day) where obtained
from the Department of Rheumatology and Clinical Immu-
nology, Charite ´-Universita ¨tsmedizin Berlin. The control
group was age-adjusted to the study cohort (mean/median
age for GBM group 55.3/58.6; mean/median age for control
group 55.2/51.7). Clinical data and histopathological data
for all patients were deposited in a phenotype-database
(SecBase). Tumor volumes were approximated from
MRI images using V(mm
3) = 4/3 9 p 9 r(sag) 9 r(ax) 9
r(cor), or from removed tumor masses, where possible.
Patient data are shown in Table 1. Peripheral blood was
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123collected before surgery and serum was separated within 2–
12 h, sub-divided, and stored at -80C until use. We
determined that no signiﬁcant change in serum concentra-
tions for the tested proteins occurred in this time window.
All samples and data were acquired in accordance with
applicable ethical standards and approved by the local
ethics review boards.
Selection of candidate serum marker proteins
Genes potentially overexpressed in astrocytoma cells were
identiﬁed by use of expression proﬁles in the serial analysis
of gene expression (SAGE) database (http://cgap.nci.nih.
gov/SAGE) using the Gene Expression Displayer tool as
described [29]. The SAGE data for 24 astrocytoma and 12
normal brain samples were compared. RNA tags with more
than a ﬁvefold difference in their relative expression level in
astrocytic tumors, and which are described by their Gene
ontology (GO) annotations as coding for potentially secre-
ted proteins, were selected. For analysis, a database was
built in which the astrocytoma gene and protein expression
levels were listed. GO terms were associated with each
entry. In addition, clinical data, tumor features, and
previous reports on the presence of speciﬁc proteins in
serum, where available, were recorded in the database. The
GO terms used for selection of candidate secreted proteins
were extracellular/extracellular space/matrix, cell surface
receptor/integral to membrane, basement membrane, cell
growth/maintenance, cell–cell-signaling/cell communica-
tion, cell motility, cell adhesion, cytokine activity, and the
non-GO annotation serum factor. The terms were selected
for their association with extracellular location and there-
fore enhanced likelihood of presence in the circulation [15,
16]. Candidate serum markers were further veriﬁed using
published data on gene and protein overexpression in
astrocytic tumors [1–5, 9, 12, 13, 19, 30–32].
Serum analysis
Serumsampleswere analyzed usingcommercially available
ELISA kits for platelet factor 4 (PF4) (Diagnostica Stago,
Asnieres-Sur-Seine, France), serotonin (IBL Immuno-Bio-
logical Laboratories, Hamburg, Germany), bone morpho-
genic protein 2 (BMP2), tumor necrosis factor-beta (TNF-b),
stem cell factor (SCF/KITLG), insulin-like growth factor
binding protein-3 (IGFBP3), chemokine (CXC motive)
Table 1 Selected clinical data
for GBM patients included in
this study
All patients had diagnosed
GBM IV. Diagnostic groups
were divided according to
survival less than or more than
15 months post surgery. All
patients received radiation
therapy
PCV, combination of
procarbazine, lomustine, and
vincristine; PEV, combination
of cisplatin, epirubicin, and
vinorelbine; n.d., not
determined
No. Survival
([15 months)
Tumor volume
(cm
3)
Survival (months) Age Radiation Chemotherapy
10 Yes 32.3 34.6 55.0 Yes Temozolomide
13 Yes 1.2 38.6 25.8 Yes Temozolomide
12 Yes n.d. 27.4 24.7 Yes Adjuvant PCV
17 Yes 0.2 33.7 50.2 Yes Temozolomide
18 Yes 2.4 43.6 78.8 Yes Temozolomide
11 Yes n.d. 44.7 36.2 yes Carboplatin, thalidomide
19 Yes 4.2 58.9 53.7 Yes Carboplatin, thalidomide
14 Yes 0.5 25.4 46.6 Yes No
23 Yes 27 72.7 41.9 Yes Temozolomide
5 Yes 54 21.8 66.7 Yes Temozolomide
22 Yes n.d. 20.0 63.9 Yes No
7 Yes n.d. 17.2 64.7 Yes Temozolomide, PCV
Mean 15.225 36.6 50.7
15 No n.d. 5.0 36.0 Yes Temozolomide
16 No 2.4 2.5 69.8 Yes Temozolomide
21 No 96 7.6 56.7 Yes Temozolomide
20 No 1.4 5.6 64.5 Yes Carmustine
8 No 50 7.1 68.6 Yes No
3 No 1.2 14.2 42.6 Yes Temozolomide
1 No 10 6.1 58.7 Yes No
9 No 6.7 10.2 58.6 Yes No
4 No 1.5 7.2 65.0 Yes Temozolomide
2 No n.d. 11.2 72.2 Yes No
6 No 0.9 11.1 70.8 Yes Temozolomide
Mean 18.9 8.0 60.3
J Neurooncol (2011) 102:71–80 73
123ligand 10 (CXCL10), interleukin-1a (IL-1a), fractalkine/
chemokine (CX3C motive) ligand 1 (CX3CL1) (R&D Sys-
tems, Minneapolis, MN, USA), thrombospondin-1 (TSP1)
(Chemicon International, Ternecula, CA, USA), heat shock
70-kDa protein (HSP70) (Stressgen Biotechnologies, VIC,
Canada), retinol-binding protein-4 (RBP4) (American
Laboratory Products Company, Windham, USA), and mid-
kine (MDK) (CellSignals, Yokohama, Japan). Serum con-
centrations for fatty acid binding protein-7 (FABP7)
(Sanbio, Munich, Germany) were determined by slot-blot
analysis (Bio-Rad Laboratories, Munich, Germany). All
samples were tested at least in triplicate. Speciﬁc concen-
tration standards for the tested factors were always included
in the assays and standard adjustment of serum samples was
performed before testing.
Histology and immunohistochemistry
Wecompiledsamplesfromtwoorthreerepresentativeareas
of 15 different GBM on a tissue micro array (TMA) as
previously described [33]. Kidney, liver and non-neoplastic
brain (temporal lobe tissue resected from epilepsy patients)
specimens from different subjects served as controls. The
TMA were probed with antibodies against HSP70 (Stress-
gen Biotechnologies), IGFBP3, TSP1 (Calbiochem, Bad
Soden, Germany), BMP2 (R&D Systems), MK (CellSig-
nals), andFABP-7(kindly providedby Dr T. Mu ¨ller, Berlin,
Germany). Immunohistochemistry was performed using a
BenchMark Automatic Staining Instrument (Ventana Med-
ical Systems, Strasbourg, France). Brieﬂy, parafﬁn sections
were rehydrated and blocked in 10% serum. Automated cell
conditioning for enhancement of antigen presentation was
performed at 95C for 8 min, at 100C for 44 min, and at
42C for 2 min. Primary antibodies were applied manually
followed by incubation at 42C for 30 min then subsequent
automated application of biotinylated secondary antibody,
horseradish peroxidase-labelled streptavidin, and DAB
staining (Ventana Medical Systems) with intermediate
washing steps. Finally, automated application of counter-
stain and bluing reagent (Ventana Medical Systems) was
performed. Immunostaining was semiquantitatively scored
by a histoscore index (percentage of positive cells 9 stain-
ing intensity) in a blinded fashion.
Data analysis
For detecting associations between the serum protein
concentration data set and the clinical diagnosis and sur-
vival time data sets, the association rule discovery method
[34] implemented by the software Magnum Opus of
RuleQuest [35] was used. Magnum Opus employs unique
k-most-interesting pattern-discovery techniques. We used
the Windows version of Magnum Opus V2.3. Association
rules found were selected manually to build decision trees
for predictive engines [36]. In the ﬁrst step all patient sets
were combined to establish the decision tree (training set).
The test sets are copies of the training set. Further, to
validate the associations found by the applied method we
performed bootstrapping, because this is generally superior
to ANOVA for small data sets [37]. In this step we sub-
sequently excluded one case from the training set and
rebuilt the decision tree with the reduced training set. The
excluded case was then used to test the reduced training
set. The bootstrap results were obtained by repeating this
procedure for all cases of the data set. They represented a
well-validated and solid outcome.
Table 2 Diagnostic candidate
proteins selected for serum
proﬁling in healthy and
astrocytoma subjects
Results are given as mean serum
concentrations, the unit is
indicated in the left row
n.d., not determined
Candidate protein Function Mean serum
concentration
astrocytoma (SD)
Mean serum
concentration
control (SD)
P value (t test)
HSP70 (ng/ml) Anti-apoptotic 0.23 (39) 0.15 (0.06) 0.09
BMP2 (pg/ml) Cell proliferation 209 (157) 176 (58.4) 0.33
RBP4 (lg/ml) Retinoic-metabolism 64.2 (5.0) 39.4 (16.1) 0.02
IGFBP3 (lg/ml) Pro-apoptotic 4.28 (1.5) 4.21 (1.2) 0.87
TSP1 (lg/ml) Anti-angiogenic 77.7 (26.4) 67.2 (36.7) 0.37
CXCL10 (pg/ml) Cell motility 34.2 (36) 105.4 (78.8) 0.001
CX3CL1 (ng/ml) Cell motility 1.65 (1.9) 2.3 (3.4) 0.44
MDK (ng/ml) Pro-angiogenic 739 (423) 243 (55) 0.07
TNFB (pg/ml) Cytokine 0 (-46.7) 0 (0) n.d.
SCF (pg/ml) Cell proliferation/
migration
440.6 (168.8) 728 (362.6) 0.032
IL1A (pg/ml) Pro-inﬂammatory 0 (0.004) 0 (0.002) n.d.
PF4 (UI/ml) Anti-angiogenic 200 (33) 218.6 (28) 0.19
Serotonin (ng/ml) Neurotransmitter 221.7 (85.4) 341.8 (88.4) 0.038
FABP7 (ng/ml) Fatty acid binding 6.5 7.2 n.d.
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123For statistical analysis of serum protein concentrations
for each of the 14 single candidate proteins, a t test was
applied. The validity of the test was calculated by use of
Fisher’s exact test.
Results
Identiﬁcation and selection of proteins potentially
secreted by astrocytoma
SAGE expression data revealed 328 mRNA species highly
expressed or underrepresented in astrocytomas compared
with normal brain tissue. Thirty-six of these were identiﬁed
as potentially astrocytoma-secreted transcripts based on
GO-term assignments. Thirty-two proteins were identiﬁed
by screening previously published gene and protein
expressiondatafromglioma[2–5,9,12,13,24,30–32].The
ﬁnal pool of candidate serum markers consisted of 68 pro-
teins. Based on the availability of suitable detection systems
14 of the 68 candidate proteins were selected (Table 2).
Serum analysis of single candidate proteins
Analysis (t test) of serum protein concentrations for each of
the 14 candidate proteins revealed raised serum concen-
trations in GBM patients compared with controls for HSP70
(p = 0.09), RBP4 (p = 0.02), serotonin (p = 0.04), and
SCF (p = 0.03), and reduced serum concentrations for
CXCL10 (p\0.001). Slightly different serum levels were
found for BMP2, TSP1, MDK, PF4, and CX3CL1
(p\0.1). No differences were found between the two
groups for IGFBP3, IL-1a, and TNF-b. For FABP7, results
were not reproducible with the antibodies used. There was
no correlation between the size of the tumor at diagnosis
and the serum protein levels of any of the tested peptides,
based on the limited number of subjects with available
tumor volume (Table 1). No signiﬁcant serum protein
concentration difference was found between patients with
rheumatoid arthritis (RA) and healthy subjects for the pro-
teins tested (data not shown).
The GBM group was subdivided into two groups com-
prising patients survivingmore than 15 month (n = 12) and
those surviving less than 15 month post surgery (n = 11).
Signiﬁcant differences in serum protein concentration
between these groups were found for TSP1 (p = 0.001) and
IGFBP3 (p = 0.03) (t test).
Data mining analysis reveals protein proﬁles in GBM
serum
Non-supervised data mining was used to propose potential
diagnostic serum protein proﬁles consisting of at least
two proteins. Thresholds of serum protein concentrations
for maximum differentiation between GBM and control
group were: 208 pg/ml (BMP2), 0.24 ng/ml (HSP70),
3.8 lg/ml (IGFBP3), 32.8 lg/ml (TSP1), 33.9 lg/ml
Table 3 Potential diagnostic serum protein proﬁle (BMP2, Hsp)
associated with the clinical feature presence of a GBM
BMP2 Hsp70 CXCL10 Diagnosis Prognosis Results
737.8 160.799 7.6 GBM GBM True positive
303.1 63.709 42.0 GBM GBM True positive
632.5 9.853 23.4 GBM GBM True positive
123.8 5.077 16.9 GBM GBM True positive
223.8 37.714 29.8 GBM GBM True positive
393.1 1.943 139.7 GBM GBM True positive
227.1 \0.024 16.6 GBM GBM True positive
180.8 \0.024 19.0 GBM GBM True positive
83.8 0.351 34.7 GBM GBM True positive
109.1 \0.024 72.0 GBM Healthy False negative
225.1 0.950 53.6 GBM GBM True positive
185.8 0.072 7.4 GBM GBM True positive
257.1 0.044 24.12 GBM GBM True positive
107.1 0.649 146.9 GBM GBM True positive
117.9 0.351 6.8 GBM GBM True positive
114.6 \0.024 -0.17 GBM GBM True positive
373.8 0.064 11.4 GBM GBM True positive
158.8 0.344 19.9 GBM GBM True positive
161.3 0.538 81.8 GBM GBM True positive
117.1 0.138 19.3 GBM GBM True positive
107.1 0.520 13 GBM GBM True positive
132.9 0.210 38.6 GBM GBM True positive
112.1 1.270 21.5 GBM GBM True positive
207.8 \0.024 67.9 Healthy Healthy True negative
179.6 0.024 49.9 Healthy Healthy True negative
116.3 \0.024 102.8 Healthy Healthy True negative
125.4 0.061 93.7 Healthy Healthy True negative
140.8 \0.024 114.3 Healthy Healthy True negative
193.8 \0.024 65.5 Healthy Healthy True negative
132.1 0.052 76.6 Healthy Healthy True negative
120.4 0.217 153.4 Healthy GBM False positive
156.3 0.130 344.0 Healthy Healthy True negative
Absolute %
True positive 22 96
True negative 8 89
Sum true 30 94
False positive 1 11
False negative 1 4
Sum false 2 6
Serum concentrations were analyzed using commercially available
ELISA kits. Protein proﬁles were identiﬁed by association analysis
and conﬁrmed by prognostic bootstrapping. Concentration for BMP-2
and CXCL10 in pg/ml. Concentration for HSP70 in ng/ml
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123(RBP4), 299 ng/ml (MDK), 1.1 ng/ml (CX3CL1), and
65.5 pg/ml (CXCL10). Except for CXCCL1 and CXCL10,
protein concentrations above these thresholds were asso-
ciated with a GBM. No thresholds were found for the
concentrations of the remaining proteins (serotonin, SCF,
MDK, FABP7, PF4, IL-1a, and TNF-b).
The deﬁned threshold concentrations were subsequently
used for identiﬁcation of protein proﬁles by association
analysis. The serum proﬁle formed by BMP2, CXCL10,
and HSP70 was associated with the clinical feature pres-
ence of GBM (Table 3, Fig. 1a). The proﬁle correctly
assigned 96% of the GBM subjects and 89% of control
subjects by bootstrap validation (p\0.0001, Fisher’s
exact test).
For the clinical feature 15 months survival post surgery,
association was achieved with serum proﬁles based on
concentrations of TSP1, HSP70, and IGFBP3. Whereas
analysis of TSP1 alone predicts the survival chance for 80%
of the GBM patients, inclusion of the other two factors
increased predictability to 100%, as validated by a bootstrap
algorithm (p\0.0001, Fisher’s exact test) (Table 4,
Fig. 1b, c). The two survival groups were not distinguished
by different treatment schemes, because these were com-
parable—standard palliative therapy including radio and
chemotherapy was used for both groups (Table 1). There
was also no association between tumor size and survival.
Although the mean age for the long-term survivor group
was 50.7 years compared with 60.3 years for the short-term
Fig. 1 Decision trees. a Clinical feature presence of a GBM.
Potential diagnostic serum protein proﬁle BMP2, CXCL10, and
HSP70. Concentrations of BMP-2 and CXCL10 in pg/ml. Concen-
tration of HSP70 in ng/ml. b Clinical feature 15 months survival post
surgery. Potential diagnostic serum protein proﬁle TSP1, HSP70, and
IGFBP3. Concentrations of TSP1 and IGFBP3 in lg/ml. Concentra-
tion of HSP70 in ng/ml. c Comparison of serum concentrations for
Hsp70, IGFBP3, and TSP1 between the groups S (survival
\15 months) and L (survival more than 15 months) of the study
cohort
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123group (non-signiﬁcant, p = 0.095, t test), the serum protein
proﬁle did not correlate with age.
Immunohistochemical detection of secreted candidate
proteins in glioblastoma
Immunohistochemistry showed strong cytosolic expression
of HSP70 and FABP7 in most GBM (Fig. 2). Some tumor
cells showed nuclear presence of FABP7. Strong nuclear
and perinuclear immunostaining of tumor cells was
detected for TSP1, whereas IGFBP3 was expressed mod-
erately in the cytoplasm. MDK expression was diffusely
present in a minority of the tumors. BMP2 expression was
negligible (not shown). In control brain sections IGFBP3
was not detectable. HSP70 was only detected in neurons
and in a small number of astrocytes, TSP1 was strongly
expressed and FABP7 expression was found in reactive
astrocytes. Histoscore data for individual tumors and serum
levels of matched samples did not correlate, even when
tumor size was taken into account (not shown).
Discussion
This is the ﬁrst study to search systematically for a diag-
nostic serum proﬁle in GBM patients. Single molecular
markers are mostly insufﬁcient to follow the dynamics of
diseases such as cancer, and will be replaced by multiple
marker proﬁles [38]. The number of proteins needed for a
deﬁned proﬁle is not known, and most likely varies
between diseases. In gene expression-based diagnostics,
proﬁles often consist of\10, but some times of more than
20 genes [32, 39]. To obtain an estimate of this number in
GBM, we analyzed serum samples of a small cohort of
GBM patients and controls and adopted data mining to
detect protein proﬁles. The data mining method used here
delivered a testable hypothesis.
Currently, few secreted proteins expressed by astrocy-
tomas have been proposed as potential serum markers
[18–27]. When tested in serum, none of these was sufﬁ-
ciently speciﬁc to serve as a diagnostic marker. We evalu-
ated the serum concentrations of 14 proteins, which were
selected by screening gene and protein expression proﬁles
of astrocytomas for proteins potentially released by the
tumor cells [15]. Included were also two classes of cyto-
plasmic proteins associated with cell stress (HSP70) [40]
and with neural stem cells (FABP7) [41]. Members of both
protein classes have previously been found in serum and
proposed as biomarkers [42, 43]. More generally, evalua-
tion of the serumproteome revealed that numerous typically
cytoplasmic proteins are found in serum [44].
In contrast with single biomarkers, in a complex diag-
nosticproﬁleofmultipleproteinsitmaynotbenecessaryfor
the concentrations of each protein to be signiﬁcantly dif-
ferentbetweentwogroups.Ourresultsareinagreementwith
this assumption. Using the complete dataset to identify
patterns of proteins by applying data mining, it was possible
toassociatecombinations ofserumproteinswith theclinical
diagnosis ‘‘presence of a GBM’’. A proﬁle with a relatively
small number of proteins (BMP2, CXCL10, HSP70) was
sufﬁcient to correctly assign 96% of the GBM and 89% of
the control subjects. One subject from the GBM and one
fromthe controlgroupweremisdiagnosedusingthis proﬁle.
The proteins constituting the identiﬁed GBM proﬁles
are functionally diverse and not directly correlated with
Table 4 Potential diagnostic serum protein proﬁle (TSP1, HSP70,
and IGFBP3) associated with the clinical feature 15-month survival
post surgery
Hsp70 IGFBP3 TSP Diagnosis Prognosis Results
160.799 3891.4 88.34 Survived Survived True negative
63.709 3753.8 110.1 Survived Survived True negative
9.853 4273.7 88.24 Survived Survived True negative
5.077 3280.7 70.3 Dead Dead True positive
37.714 5130.7 74.3 Survived Survived True negative
1.943 2080.4 47.56 Dead Dead True positive
\0.024 3175.8 67.2 Dead Dead True positive
\0.024 3208.4 59.6 Dead Dead True positive
0.351 4075.5 52.3 Dead Dead True positive
\0.024 4229.4 32.9 Dead Dead True positive
0.950 3327.3 113.93 Survived Survived True negative
0.072 4019.6 77.61 Dead Dead True positive
0.044 4907.7 19.84 Dead Dead True positive
0.649 5229.4 79.2 Survived Survived True negative
0.351 4963.7 95.6 Survived Survived True negative
\0.024 3658.3 80.3 Dead Dead True positive
0.064 4264.3 131.99 Survived Survived True negative
0.344 3766.5 105.16 Survived Survived True negative
0.538 1695.7 84.08 Survived Survived True negative
0.138 7039.7 48.4 Dead Dead True positive
0.520 3411.8 86.08 Survived Survived True negative
0.210 3273.3 82.12 Dead Dead True positive
1.270 5398.6 71.14 Survived Survived True negative
Absolute %
True positive 11 100
True negative 12 100
Sum true 23 100
False positive 0 0
False negative 0 0
Sum false 0 0
Serum concentrations were analyzed using commercially available
ELISA kits. Protein proﬁles were identiﬁed by association analysis
and conﬁrmed by prognostic bootstrapping. Concentrations of TSP1
and IGFBP3 in lg/ml. Concentration of HSP70 in ng/ml
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123tumor status. The interferon-c (IFN-c) inducible chemokine
CXCL10, concentrations of which were reduced in GBM
patients, attracts CXCR3-receptor-carrying cells. Besides
its possible transmitter function in the brain [45], it inhibits
angiogenesis and has anti-tumor activity in vivo [46] and
its reduced concentration may thus provide a growth
advantage for GBM. HSP70 is an anti-apoptotic chaperone
with tumor-promoting activity and has been described as
overexpressed in GBM, although its overall role in this
type of cancer remains unclear [47]. Increased HSP70
antibody levels have been found in serum of lung cancer
patients, indicating that it may be a biomarker for several
tumor types [48]. BMP2 is a member of the transforming
growth factor beta (TGFbeta) family, which inhibits
growth in gliomas [49] and medulloblastomas [50],
whereas the latter tumors are able to secrete BMP2 them-
selves. On the other hand, BMP2 is linked to angiogenesis
[51, 52], which is consistent with the glioblastoma being
one of the most vascularized tumors in man [53]. The role
of BMP2 in glioblastoma has not yet been elucidated. TSP1
has tumor-inhibitory properties because of its anti-angio-
genic function. Reduced serum levels of TSP1 have been
reported in small-cell lung cancer patients [54]. Upregu-
lation of TSP1 has been shown to be expressed in micro-
vascular hyperplasia during astrocytoma progression [55]
and may explain the increased serum levels found in
patients with short survival. IGFBP3 mediates p53-depen-
dent apoptosis in GBM [56] and was associated with
enhanced survival in the GBM group in this study.
Our data suggest a method for hypothesis generation and
provide only a ﬁrst indication of the presence of GBM
speciﬁc serum proﬁles. Prospective and retrospective vali-
dation of the data on larger sample sizes will be necessary to
evaluate and, perhaps, adjust the presented proﬁles further.
Conclusion
The study shows that robust serum proﬁles for GBM are
identiﬁable by data mining based on a relatively small
study cohort. The presence of a glioblastoma was distin-
guished by serum concentrations of BMP2, CXCL10, and
HSP70 with a sensitivity of 96% and speciﬁcity of 89%
using the decision tree. The TSP1, HSP70, and IGFBP3
serum proﬁle could be used to assign a survival prognosis
in our data set. These ﬁndings will be a basis for validation
with a larger sample size and with recurrent glioma.
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